The Signia Pure C&G BCT IX is a premium-tier prescription behind-the-ear hearing aid released in 2025, earning an A grade with a SoundScore of 4.49 out of 5 in HearAdvisor's lab testing. Priced at $5,396, it ranks in the top 21% of all prescription hearing aids tested.
In our lab testing, the Pure C&G BCT IX demonstrated particular strength in speech understanding, scoring well above average in noisy environments (+1.08 points above category average) and solidly above average in quiet settings (+0.69 points). Own-voice comfort was also a standout, measuring over a full point above the category average—likely benefiting users who are sensitive to the sound of their own voice.
However, the device showed relative weaknesses in music streaming quality (-0.53 points below average) and feedback handling (-0.57 points below average). Users who prioritize streaming audio or need maximum feedback resistance may want to compare alternatives. Within the same premium price tier, the Oticon Intent (4.70) and Phonak Sphere Infinio (4.64) scored higher overall, while the Signia Active Pro IX delivers a higher score at $2,197 less.
The Pure C&G BCT IX features rechargeable batteries, hands-free calling capability, and streaming compatibility with both iPhone and Android devices. It's best suited for users who prioritize speech clarity—especially in challenging listening environments—and value own-voice comfort, while being less concerned with streaming music fidelity.
